Department Protozoology, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Nagasaki, Japan.
Trends Parasitol. 2013 Jul;29(7):318-20. doi: 10.1016/j.pt.2013.05.002. Epub 2013 Jun 11.
Until very recently, artemisinin and its derivatives were the only commercially available antimalarial drugs for which there was no reported parasite resistance. Artemisinin combination therapies (ACTs) are currently relied upon for effective malaria treatment in most regions of the world in which the disease is endemic, and their continuing efficacy is crucial if control and elimination programmes are to succeed. The loss of effectiveness of artemisinin and its derivatives to drug resistance would constitute a major disaster in the fight against malaria. To properly assess the danger posed by artemisinin resistance, and therefore enable appropriate and proportionate responses, definitions of 'artemisinin resistance' and 'ACT resistance', at both the clinical and parasitological levels, are needed.
直到最近,青蒿素及其衍生物仍然是唯一没有报道寄生虫耐药性的商业上可获得的抗疟药物。在疟疾流行的世界大多数地区,青蒿素联合疗法(ACT)目前被用于有效治疗疟疾,如果要成功实施控制和消除规划,其持续有效性至关重要。青蒿素及其衍生物因耐药性而失去效力,这将是抗击疟疾的一场重大灾难。为了正确评估青蒿素耐药性带来的危险,从而采取适当和相称的应对措施,需要在临床和寄生虫学层面上对“青蒿素耐药性”和“ACT 耐药性”进行定义。